BrainStorm Cell Therapeutics

Graphic image of a pen signing a signature while two strangelooking business people cheer

Biotech

After knock back, BrainStorm aligns with FDA on ph. 3 ALS trial

A piece of the latest comeback strategy slotted into place when the biotech revealed a written agreement with the FDA on the design of a phase 3b.

Nick Paul Taylor Apr 9, 2024 7:51am

european euros

VectorY raises $138M to push forward ALS program

Nov 13, 2023 10:26am

pumpkin ladder

J&J's medtech chief out the door—Chutes & Ladders

Oct 27, 2023 9:30am

graphic image of stick figures being pushed out of a line indicating theyre being removed or fired

BrainStorm lays off 30%, details bid to reach ALS market

Oct 24, 2023 9:17am

FDA

BrainStorm eyes FDA meeting to find path for rejected drug

Oct 18, 2023 10:44am

Graphic image of a red thumbs down against a blue background

FDA advisers resoundingly reject BrainStorm's ALS drug

Sep 27, 2023 6:04pm